Hepatic Encephalopathy Treatment Guidelines

Primary Treatment Approach

Lactulose is considered the first-line treatment for hepatic encephalopathy, with rifaximin typically added as an adjunctive therapy, as recommended by the Clinical and Molecular Hepatology and Liver International guidelines 1, 2
For acute hepatic encephalopathy, lactulose should be started at 30-45 mL (20-30 g) every 1-2 hours until at least 2 soft bowel movements are produced daily, according to the Clinical and Molecular Hepatology and Praxis Medical Insights guidelines 1, 3
Rifaximin is most commonly used for prevention of recurrent episodes of hepatic encephalopathy rather than as monotherapy for acute episodes, as stated by the Liver International guideline 2, 4

Alternative dosing of 400 mg three times daily has also been used in some clinical settings, as mentioned in the Clinical and Molecular Hepatology guideline 1
Maximum recommended dose is 1,200 mg/day, which may limit its use in severe hepatic encephalopathy, according to the Clinical and Molecular Hepatology guideline 1

Most clinical evidence supports using rifaximin in combination with lactulose rather than as monotherapy, as recommended by the Liver International guideline 2, 4
French guidelines suggest rifaximin alone may be considered when lactulose is poorly tolerated, though this is based on expert opinion rather than robust clinical evidence, as stated by the Liver International guideline 2, 4

For patients with severe hepatic encephalopathy who cannot take oral medications, lactulose enemas (300 mL lactulose mixed with 700 mL water) are recommended rather than rifaximin, according to the Clinical and Molecular Hepatology and Praxis Medical Insights guidelines 1, 3

For first-line treatment of hepatic encephalopathy: Start with lactulose 20-30 g (30-45 mL) 3-4 times daily, titrated to achieve 2-3 soft stools per day, as recommended by the Clinical and Molecular Hepatology and Praxis Medical Insights guidelines 1, 3
For prevention of recurrent episodes: Add rifaximin 550 mg twice daily if lactulose alone fails to prevent recurrence, according to the Liver International guideline 2, 4
Consider rifaximin monotherapy (550 mg twice daily) only when lactulose is poorly tolerated, as recommended by the Liver International guideline 2, 4
For severe hepatic encephalopathy with inability to take oral medications: Use lactulose enemas rather than rifaximin, according to the Clinical and Molecular Hepatology and Praxis Medical Insights guidelines 1, 3

The American Association for the Study of Liver Diseases recommends that rifaximin should not be used alone for acute overt hepatic encephalopathy, as the evidence shows that while rifaximin demonstrates beneficial effects on HE resolution and mortality, analysis of potential biases in the supporting trials indicates it cannot be recommended as monotherapy for acute episodes 5, 6
Rifaximin 550 mg twice daily added to lactulose reduces recurrence risk by 58% compared to placebo in patients with at least two prior resolved episodes of overt HE, with a significant reduction in breakthrough HE episodes 5

The American College of Gastroenterology recommends adding rifaximin 550 mg twice daily to lactulose if lactulose alone fails to prevent recurrence, as this combination has been shown to be effective in preventing recurrent episodes of HE 5, 6
Rifaximin 550 mg twice daily should not be used as monotherapy for acute overt HE episodes, as lactulose remains the cornerstone of acute treatment, but may be considered as monotherapy only when lactulose is poorly tolerated 5, 6

Rifaximin significantly reduces HE-related hospitalizations and improves quality of life, with a hazard ratio of 0.50 for hospitalization involving hepatic encephalopathy 5
Rifaximin does not increase the risk of bacterial resistance or Clostridium difficile-associated colitis based on 13 randomized controlled trials, and demonstrates a good safety profile with adverse events similar to placebo, even with long-term use exceeding 24 months 5, 6

The American Association for the Study of Liver Diseases recommends that rifaximin should not be prescribed as monotherapy for acute overt HE episodes, despite its beneficial effects, as lactulose remains the cornerstone of acute treatment 5, 6
Patients should be educated that rifaximin is a long-term preventive therapy, and that the benefits are most pronounced in preventing recurrent episodes rather than treating acute presentations, to improve adherence and outcomes 5, 6

The American Association for the Study of Liver Diseases recommends rifaximin 550 mg twice daily for long-term continuous therapy to prevent recurrent hepatic encephalopathy, with no increased risk of adverse events, bacterial resistance, or Clostridium difficile infection, in patients with a history of hepatic encephalopathy 7
Rifaximin 550 mg twice daily should be continued indefinitely as maintenance therapy after a second breakthrough episode, typically combined with lactulose, to prevent recurrent overt hepatic encephalopathy in patients with cirrhosis 8

The European Association for the Study of the Liver and the American Association for the Study of Liver Diseases guidelines state that metronidazole should only be used as short-term therapy for hyperammonemia due to significant risks of ototoxicity, nephrotoxicity, and peripheral neuropathy with prolonged use, and is classified as an "alternative choice" for short-term treatment of overt hepatic encephalopathy 8
Metronidazole is recommended for use for no more than 1-2 weeks due to toxicity concerns, and should be reserved for short-term alternative therapy when rifaximin is unavailable or contraindicated, in patients with acute hepatic encephalopathy 9

The recommended first-line acute treatment for hyperammonemia is lactulose 20-30 g orally 3-4 times daily, titrated to 2-3 soft stools per day, with rifaximin 550 mg twice daily added for acute episodes, in patients with hepatic encephalopathy 7, 10
Rifaximin 550 mg twice daily should be continued indefinitely after a second breakthrough episode, with ongoing lactulose, to prevent recurrent overt hepatic encephalopathy in patients with cirrhosis 8

The American Association for the Study of Liver Diseases recommends against using metronidazole for chronic maintenance therapy due to the risk of neurotoxicity, and instead recommends rifaximin for long-term prevention of recurrent hepatic encephalopathy, in patients with cirrhosis 8, 9
Rifaximin should not be discontinued after initial improvement, as recurrence rates are high, and continuous prophylaxis is necessary to prevent recurrent hepatic encephalopathy in patients with cirrhosis 7, 10